References

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. Journal of  Viral Hepatitis 2004; 11: 97-107.

2.  Chen SL, Morgan TR.The natural history of hepatitis C virus (HCV) infection. International Journal of Medicine and Science 2006; 3: 47-52.

3.  World Health Organization. Hepatitis B: Fact Sheet. Geneva: World Health Organization, 2012.
Available at: http://www.who.int/mediacentre/factsheets/fs204/en/

4.  Tran TT. Managmenent of hepatitis B in pregnancy:  Weighing the options.  Cleveland Clinic Journal of Medicine 2009; 76(3):  525-9.

5.  Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989; 1(8643): 889-993.

6.  Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver International 2009; 29(s1): 89-99.

7.  Wiese M, Grungreiff K, Guthoff W, et al. Outcome in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 25-year multicenter study. Journal of Hepatology 2005; 43(4): 590-8.

8.  Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C between Caucausians and African Americans. Clinical Gastroenterology and Hepatology 2004; 2: 469-73.

9.  Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency infection on the course of hepatitis C virus infection: a meta-analysis. Clinicially Infectious Disease  2001; 33: 562-9.

10. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. American Journal of Gastroenterology 2002; 97: 2408-14.

11.  Ratziu V, Munteanu M, Charlotte F, et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. Journal of Hepatology 2003; 39: 1049-55.

12.  Newell ML, Pembrey L. Mother-to-child transmission of hepatitis C virus infection. Drugs of Today 2002; 38: 321-7.

13.  Memon MI, Memon MA. Hepatitis C: An epidemiological review. Journal of Viral Hepatitis 2002; 9(2): 84-100.

14. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected males : an international, multicentre study. Blood 1992; 80: 540-3.

15.  Wandeler G, Gisponer T, Bregenser A, et al.  Hepatitis C virus infections in the Swiss HIV cohort study:  A rapidly evolving epidemic.  Journal of Clinically Infectious Diseases 2012; 55(11): 1408-16.

16.  Miller CL, Wood E, Spittal PM, et al. The face of co-infection, prevalence and incidence of HIV and hepatitis C virus co-infection among injecting drug users. AIDS 2004; 36(2): 743-9.

17.  Public Health Agency of Canada. Epi-Update: Hepatitis B Infection in Canada. Ottawa: Public Health Agency of Canada, 2011.
Available at: http://www.phac-aspc.gc.ca/id-mi/pdf/hepB-eng.pdf

18. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.

19.  Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Annals of Internal Medicine 2012; 156(4): 317-8.

20.  Chevaliez S, Rodriguez C, Pawlotsky J-M. New virologic tools for the management of chronic hepatitis B and C. Gastroenterology 2012; 142: 1303-13.

21. Canadian Liver Foundation. Ontarians Deserve Better Access to Treatment for Hepatitis B and C. December, 2010.
Available at: http://www.liver.ca/print/Liver_News/livernews12151001.aspx

22.  Scaglione SJ, Lok ASF. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142: 1360-8.

23.  Public Health Agency of Canada. Reported Cases and Rates of Hepatitis C, by Province/Territory and Sex, 2005 to 2009. Ottawa: Public Health Agency of Canada, 2010.

24.  Public Health Agency of Canada. Hepatitis C in Canada: 2005-2010 Surveillance Report. Ottawa: Public Health Agency of Canada, 2011.

25.  Glasgow KW, Schabas R, Yuen MF, et al. A population-based hepatitis B seroprevalence and risk-factor study in a northern Ontario town. Canadian Journal of Public Health 1997; 88(2): 87-90.

26.  Stratton E, Sweet L, Latorraca-Walsh A, et al. Hepatitis C in Prince Edward Island: A descriptive review of reported cases, 1990-1995. Canadian Journal of Public Health 1997; 88(2): 91-4.

27.  Uhanova J, Tate RB, Tataryn DJ, et al. A population-based study of the epidemiology of hepatitis C in a North American population. Journal of Hepatology 2012; 57: 736-42.

28.  Zou S, Zhang J, Tepper M, et al. Enhanced surveillance of acute hepatitis B and C in four health regions in Canada, 1998 to 1999. Canadian Journal of Infectious Diseases 2001; 12(6): 357-63.

29.  O’Brien SF, Xi G, Fan W. et al. Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008; 48: 2323-30.

30.  Moloughney B, Kyle V, Poliquin L, et al. A health care needs assessment of federal inmates in Canada. Canadian Journal of Public Health 2004; 95(Supp1.): S9-63.

31.  Public Health Agency of Canada. Sexually Transmitted Infections in Canadian Street Youth—Findings from Enhanced Surveillance of Canadian Street Youth, 1999-2003. Ottawa: Public Health Agency of Canada, 2006.
Available at: http://www.phac-aspc.gc.ca/std-mts/reports_06/pdf/sti-street_youth_e.pdf

32.  Poulin C, Gyorkos T, Joseph L, et al. An epidemic of hepatitis B among injection drug users in a rural area. Canadian Journal of Public Health 1992; 83: 102-5.

33.  Remis RS. Modeling the Incidence and Prevalence of Hepatitis C Infection and Its Sequelae in Canada, 2007. Final Report.
Available at: http://www.phac-aspc.gc.ca/sti-its-surv-epi/model/index-eng.php

34.  Public Health Agency of Canada.  Case definitions for communicable diseases under national surveillance.  Canadian Communicable Disease Report 2009; 35(S2). 
Available at:  http://www.hac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s2/index-eng.php

35.  Giroux S,  Labrecque F, Quigley A. Sampling Documentation for Cycle 2 of the Canadian Health Measures Survey. Methodology Branch Working Paper 002. Ottawa: Statistics Canada, 2013.

36.  Day B, Langlois R, Tremblay M, Knoppers BM. Canadian Health Measures Survey: Ethical, legal and social issues. Health Reports 2007; 18(Suppl.): 37-51.

37.  Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 1 2010. Available at: http://www.statcan.gc.ca/imdb-bmdi/document/5071_D2_T1_V1-eng.pdf

38.  Statistics Canada. CHMS Cycle 2 documents. List of Available Canadian Health Measures Survey (CHMS) Documents. Ottawa: Statistics Canada,2013.
Available on request at: http://www23.statcan.gc.ca/imdb-bmdi/document/5071_D4_T9_V1-eng.htm

39.  Bryan S, St. Denis M, Wojtas D. Canadian Health Measures Survey: Clinic operations and logistics. Health Reports 2007; 18(Suppl.): 53-71.

40.  Statistics Canada. Census Webpage. Ottawa: Statistics Canada, 2013.
Available at:  http://www12.statcan.gc.ca/census-recensement/index-eng.cfm?HPA

41.  Lavanchy D. The global burden of hepatitis C. Liver International 2009; Suppl. 1: 74-91.

42.  Centres for Disease Control and Prevention. Travelers’ Health—Yellow Book, 2008. Atlanta, Georgia: U.S. Department of Health and Human Services.

43.  Health Canada.  Case definitions for communicable diseases under national surveillance.  Canadian Communicable Disease Report 2000; 26(S3). 
Available at:  http://publications.gc.ca/collections/Collection/H12-21-3-26-3E.pdf

44.  Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20: 1447-50.

45.  Rao JNK, Wu GFJ, Yue K. Some recent work on resampling methods for complex surveys. Survey Methodology (Statistics Canada, Catalogue 12-001) 1992; 18: 209-17.

46.  Rust KF, Rao JNK. Variance estimation for complex surveys using replication techniques. Statistical Methods in Medical Research 1996; 5: 281-310.

47.  Wasley A, Kruszon-Moran D, Kuhmert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. Journal of Infectious Diseases 2010; 202: 192-201.

48.  Rossi C, Shrier I, Marshal L, et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: A systematic review and meta-analysis. PLOS One 2012; 7(9): c44611.

49.  MacDonald NE. Moving towards a universal hepatitis B vaccine program for Canadian children. Canadian Journal of Infectious Disease 1995; 6(3): 129-30.

50.  Health Canada. Report of the Hepatitis B Working Group. Canadian Medical Association Journal 1994; 151: 1294-7.

51.  Public Health Agency of Canada. Publicly Funded Immunization Programs in Canada—Routine Schedule for Infants and Children Including Special Programs and Catch-up Programs (as of December 2012).Ottawa: Public Health Agency of Canada, 2012.
Available at: http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php

52.  Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 2006; 144: 705-14.

53.  Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of Hepatitis C in England and Wales. Journal of Infection 2002; 45: 219-36.

54.  Boulos D, Goedhuis NJ, Wu J, et al. Enhanced surveillance for acute and likely acute hepatitis B in Canada: 1999 to 2002. Canadian Journal of Infectious Diseases and Medical Microbiology 2005; 16(5): 275-81.

55.  Public Health Agency of Canada. Epidemiology of acute hepatitis C infection in Canada. Results  from the Enhanced Hepatitis Strain Surveillance System (EHSSS). Ottawa: Public Health Agency of Canada, 2006.

56.  Amin J, Gidding H, Gilbert G, et al. Hepatitis C prevalence—a nationwide serosurvey. Communicable Disease Intelligence 2004; 28(4): 517-21.

57.  Goldman M, Long A. Hepatitis C lookback in Canada. Vox Sanguinis 2000; 78(Suppl. 2): 249-52.

58.  Public Health Agency of Canada. Custom tabulation from M-Track: Enhanced surveillance of risk behaviours among gay, bisexual and other men who have sex with men in Canada, Phase 1 (2005-2007). Unpublished. Ottawa: Public Health Agency of Canada, 2012.

59.  Correctional Service Canada. Infectious Disease Surveillance in Federal Penitentiaries 2005-2006. Fall 2008.
Available at: http://www.csc-scc.gc.ca/text/pblct/infdscfp-2005-06/p12-eng.shtml

60.  Public Health Agency of Canada. Custom tabulation from I-Track: Enhanced surveillance of risk behaviours among people who inject drugs. Phase 2 (2005-2008). Unpublished. Ottawa: Public Health Agency of Canada, 2010.

61.  Public Health Agency of Canada. Custom tabulation from E-SYS: HBV+ status awareness levels among Canadian street youth surveyed between 1999 and 2012 (cycles 2-6). Unpublished. Ottawa: Public Health Agency of Canada, 2013.

62.  Spittal PM, Pearce ME, Chavoshi N, et al. The Cedar project: high incidence of HCV infections in a longitudinal study of young aboriginal people who use drugs in two Canadian cities. BMC Public Health 2012; 12: 632-42.

63.  Edlin BR. Perspective: Test and treat this silent killer. Nature 2011; 474: S18-9.

64.  Werb D, Wood E, Kerr T, et al. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. International Journal of Drug Policy 2011; 22: 70-6.

65.  Statistics Canada. Canadian Health Measures Survey (CHMS) Standard Operating Procedures for Laboratory Infection Markers: Cycle 2. Unpublished. Ottawa: Statistics Canada, 2012.

66.  Lee D-S, Lesniewski RR, Sung Y-C, et al.  Significance of Anti-E2 in the diagnosis of HCV infection in patients on maintenance hemodialysis:  Anti-E2 is frequently detected among anti-HCV antibody-negative patients.  Journal of the American Society for Nephrology 1996; 7(11):  2409-13.

67.  Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroconversion of anti-hepatitis C virus during the natural course of hepatitis C virus in the general population. Gut 2002; 50: 693-6.

68.  Centres for Disease Control and Prevention. Testing for HCV infection: An update of guidance for clinicians and laboratorians. Morbidity and Mortality Weekly Review 2013; 62(18): 362-5.